Focus:
Gilead Sciences has entered a multi-programme agreement with Second Genome to discover new targets and drug candidates for inflammatory bowel disease (IBD) treatment.
Takeda Pharmaceutical and its partner CSL Behring have teamed up with plasma companies Biotest, BPL, LFB and Octapharma to develop a hyperimmune therapy for Covid-19.
GlaxoSmithKline (GSK) has agreed to invest $250m in Vir Biotechnology for the research and development (R&D) of antibodies to treat Covid-19 infection.
Analysis of a poll conducted by Verdict to assess the impact of COVID-19 on the drug supply chain showed that 90% are either highly or partially concerned about the disruption....
Inovio Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application of its DNA vaccine candidate INO-4800 against Covid-19.
Biopharmaceutical firm XBiotech has partnered with non-profit BioBridge Global to develop a new Covid-19 therapy using natural antibodies from convalescent plasma of recovered patients.
French pharmaceutical company Servier has signed a definitive agreement to acquire 100% shares in Danish therapeutic antibody discovery firm Symphogen.
GlaxoSmithKline (GSK) has partnered with Xiamen Innovax Biotech to support the development of a recombinant protein-based vaccine candidate against Covid-19.
UK-based Izana Bioscience has launched a compassionate use study of namilumab (IZN-101) in patients with rapidly worsening Covid-19 in Bergamo and Milan, Italy.
The UK Government has announced that a large-scale randomised trial has been launched to assess potential treatments for Covid-19 (coronavirus).
Go Top
